Daiichi Sankyo aims to transform its antibody-drug conjugate leadership into a top global oncology standing. In a new five-year business plan unveiled Monday, the Japanese pharma outlined a roadmap to become a global top five oncology player by 2035, plus a major $1.3 billion cost optimization initiative.